Semaglutide, type 2 diabetes and CKD
Why is this Important?
People with type 2 diabetes and chronic kidney disease are at high risk for kidney failure, heart problems, and even death. Discovering treatments that can lower these risks is vital for enhancing patient health and longevity.
What Did the Study Show?
Recent research (“FLOW trial“) revealed that semaglutide (Ozempic for diabetes, and Wegovy for weight loss) can significantly reduce serious health risks. Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist. Patients taking semaglutide experienced a 24% lower risk of major kidney events and an 18% lower risk of major heart events compared to those on a placebo.
How Does This Affect You?
If you have type 2 diabetes and chronic kidney disease, semaglutide might be a game-changer. It can help protect your kidneys and heart, potentially extending your life and improving its quality. Consult your doctor to see if semaglutide is right for you.
Last Reviewed on 26 June 2024
